about
Cholinesterase inhibitors for mild cognitive impairmentCholinesterase inhibitors for mild cognitive impairmentTau-targeted treatment strategies in Alzheimer's diseaseComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: protocol for a systematic review and individual patient data network meta-analysisThe Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Packages of care for dementia in low- and middle-income countries.Using NMR approaches to drive the search for new CNS therapeutics.Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screeningNeurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathologyUpdate on the pharmacological treatment of Alzheimer's diseaseDetermination of high-affinity choline uptake (HACU) and choline acetyltransferase (ChAT) activity in the same population of cultured cells.Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.Acetylcholinesterase inhibitors: pharmacology and toxicology.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Rehabilitating a brain with Alzheimer's: a proposal.Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors.Dutch family physicians' awareness of cognitive impairment among the elderly.Alzheimer's disease: a clinical practice-oriented review.Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's diseaseA 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's DiseaseCompliance and Caregiver Satisfaction in Alzheimer's Disease: Results from the AXEPT Study.Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time.Management of patients with Alzheimer's disease: pharmacological treatment and quality of lifeNoninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future.Poor physical fitness is independently associated with mild cognitive impairment in elderly Koreans.Natural products as a source of Alzheimer's drug leads.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Disease-modifying drugs in Alzheimer's disease.The thickness of posterior cortical areas is related to executive dysfunction in Alzheimer's diseaseCurrent Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.First in human study with a prodrug of galantamine: Improved benefit-risk ratio?Prediction of Anti-Alzheimer's Activity of Flavonoids Targeting Acetylcholinesterase in silico.Interdisciplinary Therapy for patients with dementia.The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial.An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic reviewBasal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors
P2860
Q24200430-62BB7767-0467-4F19-BAF2-7F6A7D44578DQ24234894-EA6C3E9E-0197-48BD-8FE3-602E55D00CD2Q27023429-8312CB56-BC99-4F8F-811A-C907EE09E5A5Q28080099-27247277-5941-4CCE-B3B3-F22D4A9CEF18Q30560766-19C24A81-5468-4B6C-8D32-AF2720FBDE55Q33160127-C63AAA9A-C316-4894-B334-5F0C55F04D31Q33514859-3FDE3F74-E638-4E08-A622-624BA8920BCEQ33613767-BA3ABE87-C056-4514-B277-14C6560C3E27Q33749260-82CF6B85-89BA-4C3B-B005-F6DDE63B7F5BQ33822696-0D9C3094-2FF1-42B3-B4FB-C6C1332919F6Q33836947-150B2A16-5BE8-4761-9721-970EEC8D11BCQ33844778-1F7EF5A0-2E9D-468F-BFA0-B383A9287582Q34306253-7CC38AFB-98EA-41A3-94AC-350A3D2112E7Q34381860-77474623-DB6A-448B-A5D6-A900AECE5365Q34408888-EBFDE256-660C-4164-91AF-58FB19CD01C4Q34733254-BA3DB33A-B374-4452-875E-7B370226E673Q35056496-942CDD1E-52DD-421B-9697-1BFB01C5CBD1Q35756655-C605EBFC-9FE1-4F19-8516-4E7FDA47E072Q35899503-71D9513E-7DA6-4E85-A115-BBD721FF8EA7Q35995627-81A45414-9243-4023-8008-2D84D39D3381Q36261229-E74A972D-2129-4784-A7D6-CBC15AF320E4Q36383025-70C22B60-0144-46F2-A089-8CCD3BE028B5Q36467267-8E8353AA-885A-4E53-AB91-CBDED82495BBQ36515587-A9D88118-9E64-4710-BCF0-03C81B32E000Q36661005-FDB8A6BF-29F8-4203-A83B-3BD4D3A61B54Q36674274-B108098E-7D62-4877-B34E-04139CE72282Q37029561-E025E1FD-920E-44A6-9A30-6D05C40A0E01Q37070395-16A94E38-5A6C-4C9E-BD19-4044D5815A26Q37390739-640DE375-A733-487D-91B9-C8C427E1714CQ37408596-FC6DF555-2D87-4FF5-B976-2729039CAFD1Q38661735-ACBBAF36-D37D-490B-8C44-CEED74EAB019Q42689680-68707899-3E35-49BE-87C6-6EFC14C4F564Q46422016-F3DA8118-C7AE-4B7B-87E5-E2D9549B6F74Q47110051-BFF67F73-84C1-4D5E-82AA-4396772B892EQ47549748-3EC4E100-B850-4FDE-A21B-A0170EDE9646Q48219255-D1C2BB44-6884-4B9B-9798-0A56E06EED91Q58698874-33D8BDC4-286A-4554-88E8-31BDF1ACFFAEQ58780915-3E1E95D1-BEFC-41CB-A5A4-0C9C3B2B400E
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Rivastigmine for Alzheimer's disease
@ast
Rivastigmine for Alzheimer's disease
@en
Rivastigmine for Alzheimer's disease
@en-gb
Rivastigmine for Alzheimer's disease
@nl
type
label
Rivastigmine for Alzheimer's disease
@ast
Rivastigmine for Alzheimer's disease
@en
Rivastigmine for Alzheimer's disease
@en-gb
Rivastigmine for Alzheimer's disease
@nl
prefLabel
Rivastigmine for Alzheimer's disease
@ast
Rivastigmine for Alzheimer's disease
@en
Rivastigmine for Alzheimer's disease
@en-gb
Rivastigmine for Alzheimer's disease
@nl
P2860
P1476
Rivastigmine for Alzheimer's disease
@en
P2093
John Grimley Evans
Vasso Iakovidou
P2860
P356
10.1002/14651858.CD001191.PUB2
P577
1996-09-01T00:00:00Z